COPYRIGHT © BY THE JOURNAL OF BONE AND JOINT SURGERY,INCORPORATED
LUDWICK ET AL.
ASPIRIN MAY BE A SUITABLE PROPHYLAXIS FOR PATIENTS WITH A HISTORY OF VENOUS THROMBOEMBOLISM UNDERGOING TOTAL
JOINT ARTHROPLASTY
http://dx.doi.org/10.2106/JBJS.21.00601 Page1
The following content was supplied by the authors as supporting material and has not been copy-edited or verified by JBJS.
Supplemental Table 1. Breakdown of demographics, clinical variables, and standard mean differences for non-aspirin vs. aspirin cohorts in a 1:1 propensity score match.
Non-aspirin (n=182) Aspirin (n=182) Standard Mean
Difference (SMD) P Value
Joint: 0.459
Hip 99 (54.4%) 107 (58.8%) -0.089
Knee 83 (45.6%) 75 (41.2%) -0.089
Sex: 0.751
Female 100 (54.9%) 104 (57.1%) 0.044
Male 82 (45.1%) 78 (42.9%) -0.044
Age 66.0 (10.3) 66.0 (11.1) 0.003 0.980
BMI 30.2 (4.96) 30.1 (5.23) -0.013 0.901
CHF: 1.000
No 178 (97.8%) 178 (97.8%) 0.000
Yes 4 (2.20%) 4 (2.20%) 0.000
CPD: 1.000
No 154 (84.6%) 154 (84.6%) 0.000
Yes 28 (15.4%) 28 (15.4%) 0.000
CVD: 0.724
No 177 (97.3%) 179 (98.4%) 0.086
Yes 5 (2.75%) 3 (1.65%) -0.086
Dementia: 1.000
No 182 (100%) 181 (99.5%) -0.074
COPYRIGHT © BY THE JOURNAL OF BONE AND JOINT SURGERY,INCORPORATED
LUDWICK ET AL.
ASPIRIN MAY BE A SUITABLE PROPHYLAXIS FOR PATIENTS WITH A HISTORY OF VENOUS THROMBOEMBOLISM UNDERGOING TOTAL
JOINT ARTHROPLASTY
http://dx.doi.org/10.2106/JBJS.21.00601 Page2
Yes 0 (0.00%) 1 (0.55%) 0.074
Diabetes: 1.000
No 172 (94.5%) 171 (94.0%) -0.023
Yes 10 (5.49%) 11 (6.04%) 0.023
Hemiparesis: No 182 (100%) 182 (100%) 0.000 .
Cancer: 1.000
No 177 (97.3%) 177 (97.3%) 0.000
Malignancy 4 (2.20%) 4 (2.20%) 0.000
Metastatic 1 (0.55%) 1 (0.55%) 0.000
MI: 1.000
No 168 (92.3%) 168 (92.3%) 0.000
Yes 14 (7.69%) 14 (7.69%) 0.000
Mild Liver Disease: 1.000
No 178 (97.8%) 178 (97.8%) 0.000
Yes 4 (2.20%) 4 (2.20%) 0.000
Moderate-Severe Liver
Disease: 1.000
No 182 (100%) 181 (99.5%) -0.074
Yes 0 (0.00%) 1 (0.55%) 0.074
Peptic Ulcer: 1.000
No 179 (98.4%) 180 (98.9%) 0.053
Yes 3 (1.65%) 2 (1.10%) -0.053
PVD: 1.000
No 175 (96.2%) 174 (95.6%) -0.027
Yes 7 (3.85%) 8 (4.40%) 0.027
Renal: 0.619
No 172 (94.5%) 175 (96.2%) 0.086
COPYRIGHT © BY THE JOURNAL OF BONE AND JOINT SURGERY,INCORPORATED
LUDWICK ET AL.
ASPIRIN MAY BE A SUITABLE PROPHYLAXIS FOR PATIENTS WITH A HISTORY OF VENOUS THROMBOEMBOLISM UNDERGOING TOTAL
JOINT ARTHROPLASTY
http://dx.doi.org/10.2106/JBJS.21.00601 Page3
Yes 10 (5.49%) 7 (3.85%) -0.086
Rheumatic: 0.864
No 162 (89.0%) 164 (90.1%) 0.037
Yes 20 (11.0%) 18 (9.89%) -0.037
Number of Joints: 0.284
Bilateral 2 (1.10%) 6 (3.30%) 0.123
Unilateral 180 (98.9%) 176 (96.7%) 0.123
Type of Surgery: 0.899
Primary 141 (77.5%) 143 (78.6%) 0.027
Revision 41 (22.5%) 39 (21.4%) -0.027
Operative Time 83.8 (44.1) 84.4 (42.9) 0.015 0.889
Tranexamic Acid: 0.191
No 122 (67.0%) 109 (59.9%) -0.146
Yes 60 (33.0%) 73 (40.1%) 0.146
Cement: 1.000
No 116 (63.7%) 116 (63.7%) 0.000
Yes 66 (36.3%) 66 (36.3%) 0.000
Blood Transfusion: 0.841
No 163 (89.6%) 161 (88.5%) -0.034
One 14 (7.69%) 14 (7.69%) 0.000
Two or More 5 (2.75%) 7 (3.85%) 0.057